Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Burkitt Lymphoma 6Lymphoma, B-Cell 5Lymphoma 5Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Lymphoma, Non-Hodgkin 2Hematologic Neoplasms 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Follicular 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Leukemia 1Blast Crisis 1

Interventions

Rituximab 173Cyclophosphamide 156Vincristine 72fludarabine phosphate 71Etoposide 68Doxorubicin 68Prednisone 66Filgrastim 58Methotrexate 52Cytarabine 51fludarabine 49Melphalan 48Busulfan 47Tacrolimus 41Whole-Body Irradiation 39Mycophenolic Acid 39Granulocyte Colony-Stimulating Factor 37Antilymphocyte Serum 31Peripheral Blood Stem Cell Transplantation 30Radiotherapy 27Lenalidomide 25Dexamethasone 25Carmustine 23Stem Cell Transplantation 22Cyclosporine 22Bortezomib 22Gemcitabine 20Bendamustine Hydrochloride 20ibritumomab tiuxetan 19Alemtuzumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × Lymphoma × Inotuzumab Ozogamicin × Clear all
NCT03856216 2026-04-15

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

M.D. Anderson Cancer Center

Phase 2 Terminated
15 enrolled 11 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01232556 2019-01-08

A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Pfizer

Phase 3 Terminated
338 enrolled 15 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT00073749 2018-12-17

Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

Pfizer

Phase 1 Completed
79 enrolled 24 charts
Lymphoid

Lymphoma, Lymphoma, B-Cell

NCT00299494 2018-03-08

Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

Pfizer

Phase 1/2 Completed
119 enrolled 60 charts
Lymphoid

Lymphoma, Lymphoma, B-Cell

NCT00868608 2017-10-31

Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma

Pfizer

Phase 2 Completed
81 enrolled 24 charts
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡